Results 21 to 30 of about 2,641,102 (341)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer

Frontiers in Oncology, 2022
Ovarian cancer represents worldwide the second most frequent and the most fatal gynecological malignancy, with approximately two thirds of the patients presenting with advanced disease. Cytoreductive surgery, primary or after neoadjuvant chemotherapy, in
Eelco de Bree, Dimosthenis Michelakis, Elisavet Anagnostopoulou   +2 more
doaj   +1 more source

Selection of patients [PDF]

Journal of Medical Ethics, 1982
The author joins the discussion on selection of patients in the face of life-saving resources initiated in the Journal by Parsons and Lock, Mooney and the editorial in the December 1980 issue. In this article several selection systems are discussed. The author is in favour of a `criteria-system'. The criteria for such a system are elaborated.
openaire   +2 more sources

Evaluating candidate reactions to selection practices using organisational justice theory [PDF]

, 2011
Objectives: This study aimed to examine candidate reactions to selection practices in postgraduate medical training using organisational justice theory.
Carr, V., Gregory, S., Irish, B., Patterson, F., Zibarras, L. D.   +4 more
core   +1 more source

Association of radiation dose intensity with overall survival in patients with distant metastases

Cancer Medicine, 2021
Background Patients with metastatic cancer referred to radiation oncology have diverse prognoses and there is significant interest in personalizing treatment.
Johnny Kao, Mark K. Farrugia, Samantha Frontario, Amanda Zucker, Emily Copel, John Loscalzo, Ashish Sangal, Boramir Darakchiev, Anurag Singh, Symeon Missios   +9 more
doaj   +1 more source

Identifying multimorbid patients with high care needs - A study based on electronic medical record data

European Journal of General Practice, 2020
Background Patients with multimorbidity who frequently contact the general practice, use emergency care or have unplanned hospitalisations, may benefit from a proactive integrated care intervention. General practitioners are not always aware of who these
Marianne Heins, Joke Korevaar, Francois Schellevis, Mieke Rijken   +3 more
doaj   +1 more source

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

Clinical and Translational Medicine, 2022
Background The CD47‐signal regulatory protein alpha (SIRPα) ‘don't eat me’ signalling axis is perhaps the most prominent innate immune checkpoint to date.
Renée Bouwstra, Tom vanMeerten, Edwin Bremer   +2 more
doaj   +1 more source

Adverse outcomes in nontrial like patients on commercial HeartMate 3 LVAD support

JHLT Open, 2023
Background: Patient selection for real-world use of HeartMate 3 left ventricular assist device (HM3 LVAD) differs from that of clinical trials. We assessed adverse-event rates between “nontrial like” (NTL) and “trial like” (TL) patients who underwent ...
Laura Coyle, APN, Colleen Gallagher, BSN, Nicole Graney, APN, Lisa Kukla, APN, Robin Paliga, APN, Kylie Hughes, APN, Rachel Pedersen, BA, Kathleen Schultz, APN, Adam JT Schuldt, MD, PhD, Nasir Sulemanjee, MD, Gregory P. Macaluso, MD, Sunil Pauwaa, MD, James Monaco, MD, Mark Dela Cruz, MD, William G. Cotts, MD, Nikhil Narang, MD, Patroklos S. Pappas, MD, Antone J. Tatooles, MD, Vinh Q. Chau, MD   +18 more
doaj   +1 more source

Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort

Frontiers in Oncology, 2023
BackgroundThe role of stereotactic ablative radiation therapy (SABR) as local treatment option after chemotherapy for locally advanced pancreatic cancer (LAPC) is evolving.
D. Doppenberg, D. Doppenberg, D. Doppenberg, F. J. Lagerwaard, F. J. Lagerwaard, S. van Dieren, M. R. Meijerink, M. R. Meijerink, J. J. van der Vliet, J. J. van der Vliet, J. J. van der Vliet, M. G. Besselink, M. G. Besselink, G. van Tienhoven, G. van Tienhoven, E. Versteijne, E. Versteijne, B. J. Slotman, B. J. Slotman, J. W. Wilmink, J. W. Wilmink, G. Kazemier, G. Kazemier, A. M. E. Bruynzeel, A. M. E. Bruynzeel   +24 more
doaj   +1 more source

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC [PDF]

, 2017
Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic
Abdel-Rahman, Aguiar, Borghaei, Brahmer, Calhoun, Chen, Dent, Domingues, Doyle, Ferlay, Goeree, Hanahan, Herbst, Herbst, Huang, Hurvitz, Masters, Matter-walstra, Moro-Sibilot, Nafees, Passiglia, Petitti, Rittmeyer, Siegel, Stokes, Tartari   +25 more
core   +3 more sources

Is There a Place for Somatostatin Analogues for the Systemic Treatment of Hepatocellular Carcinoma in the Immunotherapy Era?

Livers, 2022
Patients with advanced hepatocellular carcinoma (HCC) have a very limited survival rate even after the recent inclusion of kinase inhibitors or immune checkpoint inhibitors in the therapeutic armamentarium. A significant problem with the current proposed
Elias Kouroumalis, Ioannis Tsomidis, Argryro Voumvouraki   +2 more
doaj   +1 more source